Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2015 1
2017 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP, Krueger DA. MacKeigan JP, et al. Neuro Oncol. 2015 Dec;17(12):1550-9. doi: 10.1093/neuonc/nov152. Epub 2015 Aug 19. Neuro Oncol. 2015. PMID: 26289591 Free PMC article. Review.
Everolimus is approved for subependymal giant cell astrocytomas and renal angiomyolipomas in patients with TSC. Sirolimus, though not approved for TSC, has undergone considerable investigation to treat various aspects of the disease. Everolimus and sirolimus selecti …
Everolimus is approved for subependymal giant cell astrocytomas and renal angiomyolipomas in patients with TSC. Sirolimus, though not …
The genomic landscape of tuberous sclerosis complex.
Martin KR, Zhou W, Bowman MJ, Shih J, Au KS, Dittenhafer-Reed KE, Sisson KA, Koeman J, Weisenberger DJ, Cottingham SL, DeRoos ST, Devinsky O, Winn ME, Cherniack AD, Shen H, Northrup H, Krueger DA, MacKeigan JP. Martin KR, et al. Among authors: mackeigan jp. Nat Commun. 2017 Jun 15;8:15816. doi: 10.1038/ncomms15816. Nat Commun. 2017. PMID: 28643795 Free PMC article.
Tuberous sclerosis complex (TSC) is a rare genetic disease causing multisystem growth of benign tumours and other hamartomatous lesions, which leads to diverse and debilitating clinical symptoms. ...Using immune data sets, we identify significant neuroinflammation in TS
Tuberous sclerosis complex (TSC) is a rare genetic disease causing multisystem growth of benign tumours and other hamartomatous lesio …
Chemical Biology Screening Identifies a Vulnerability to Checkpoint Kinase Inhibitors in TSC2-Deficient Renal Angiomyolipomas.
Vaughan RM, Kordich JJ, Chan CY, Sasi NK, Celano SL, Sisson KA, Van Baren M, Kortus MG, Aguiar DJ, Martin KR, MacKeigan JP. Vaughan RM, et al. Among authors: mackeigan jp. Front Oncol. 2022 Mar 10;12:852859. doi: 10.3389/fonc.2022.852859. eCollection 2022. Front Oncol. 2022. PMID: 35359406 Free PMC article.
The tuberous sclerosis complex (TSC) is a rare genetic syndrome and multisystem disease resulting in tumor formation in major organs. A molecular hallmark of TSC is a dysregulation of the mammalian target of rapamycin (mTOR) through loss-of-function mutations in eit …
The tuberous sclerosis complex (TSC) is a rare genetic syndrome and multisystem disease resulting in tumor formation in major organs. …
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors.
Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gygi SP. Ballif BA, et al. Among authors: mackeigan jp. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):667-72. doi: 10.1073/pnas.0409143102. Epub 2005 Jan 12. Proc Natl Acad Sci U S A. 2005. PMID: 15647351 Free PMC article.
Additionally, we monitored 14 previously uncharacterized and six known phosphorylation events after phorbol ester stimulation in the ERK/p90 ribosomal S6 kinase-signaling targets, the tuberous sclerosis complex (TSC) tumor suppressors TSC1 and TSC2. By using quantitative p …
Additionally, we monitored 14 previously uncharacterized and six known phosphorylation events after phorbol ester stimulation in the ERK/p90 …